Quarterly report [Sections 13 or 15(d)]

SCHEDULE OF RECONCILIATION OF ADJUSTED EBITDA (Details)

v3.26.3
SCHEDULE OF RECONCILIATION OF ADJUSTED EBITDA (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2026
Sep. 30, 2025
Sep. 30, 2026
Sep. 30, 2025
Segment Reporting [Abstract]        
(Loss) income from continuing operations (GAAP Basis) $ (1,501) $ 1,011 $ (404) $ 2,232
Depreciation and amortization 141 111 386 307
Stock-based compensation 3,993 7 4,001 31
Non-recurring legal expenses 234 614
Severance & related expense 692
Asset impairment - lab supplies 198
Loss on sale of asset 104 104
Lab supplies write-off 217
Taxes (benefit) expense (884) (11) (517) 7
Note payable interest 30 156
Other income/expense, net (15) 10 (33) 25
Change in fair value of note payable 105 87
Adjusted EBITDA $ 2,072 $ 1,263 $ 4,368 $ 3,735